What is FOXO?
FOXO Technologies operates at the intersection of healthcare services and advanced technology, utilizing artificial intelligence and machine learning to redefine health, wellness, and longevity. The firm's core focus is on the identification and commercialization of epigenetic biomarkers, which are crucial for developing personalized health strategies, enhancing underwriting processes, and advancing bioinformatics. Through its integrated laboratory, data analytics, and diagnostic capabilities, FOXO empowers insurers, researchers, and life science organizations to derive actionable health-related information. The company's proprietary epigenetics platform is designed to propel predictive health science and improve patient outcomes across the healthcare and longevity research sectors.
How much funding has FOXO raised?
FOXO has raised a total of $2.1M across 2 funding rounds:
Stock/Share Issuance
$1.5M
Private Equity
$600K
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Private Equity (2025): $600K, investors not publicly disclosed
What's next for FOXO?
With the infusion of $600K in a major strategic investment, FOXO Technologies is poised for accelerated growth and innovation. This substantial backing, adding to its overall $2.1M in capital, signals a strong market validation for its AI-driven approach to epigenetics and personalized health. The company is expected to further invest in expanding its research and development initiatives, enhancing its laboratory and data analytics infrastructure, and potentially forging new strategic partnerships. This strategic financing will likely enable FOXO to scale its operations, broaden its market reach, and solidify its position as a leader in predictive health science and longevity solutions.
See full FOXO company page
